To cite: Keystone EC, Taylor PC, Tanaka Y, et al. Annals of the Rheumatic Diseases 2017;76:1853-1861.
Read the full article here: [ Ссылка ].
Background:
To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX).
Conclusions:
Baricitinib provided significantly greater improvement in most PROs compared with placebo and adalimumab, including physical function MJS, pain, fatigue and quality of life. Improvement was maintained to the end of the study (week 52).
